4R Tauopathies | Alzheimer's Disease | Parkinson's Disease | Corticobasal Degeneration | Multiple System Atrophy | Tau Protein | MAPT Gene | Neuroinflammation | Oxidative Stress | Substantia Nigra | Microglia | Astrocytes | Globus Pallidus | Iron Metabolism | Mitochondrial Dysfunction | Autophagy Dysfunction | Ubiquitin-Proteasome System
Progressive Supranuclear Palsy (PSP), also known as Steele-Richardson-Olszewski syndrome, is a progressive neurodegenerative disorder characterized by vertical gaze palsy, postural instability, parkinsonism, and frontal cognitive dysfunction[1]. PSP is classified as a 4R tauopathy, meaning it is associated with the abnormal accumulation of the microtubule-associated protein tau in the brain[2].
PSP is now recognized as part of a spectrum of disorders with overlapping clinical and pathological features, collectively termed "PSP-spectrum disorders." These include classic PSP (Richardson syndrome), as well as variant phenotypes such as PSP-parkinsonism (PSP-P), PSP-pure akinesia with gait freezing (PSP-PAGF), and cortical syndromes such as PSP with predominant cerebellar ataxia (PSP-C) and PSP with predominant frontal presentation (PSP-F).
Progressive Supranuclear Palsy (PSP) is a 4R tauopathy characterized by the accumulation of tau protein in the brainstem, basal ganglia, and cerebellar structures. Key features include vertical gaze palsy, postural instability, and progressive akinesia. PSP is caused by tau protein dysfunction and aggregation, with the MAPT H1 haplotype as the primary genetic risk factor. The disease typically presents in the sixth decade and progresses rapidly, with a median survival of 7-9 years.
Key Pathological Features:
Clinical Presentation:
Treatment Status: No disease-modifying therapies exist; treatment is symptomatic.
PSP is a rare but not uncommon neurodegenerative disorder:
The MAPT gene on chromosome 17q21.31 represents the strongest genetic risk factor for PSP. The H1 haplotype confers an odds ratio of approximately 5.5-8.0 for PSP risk[4]. Additional risk loci identified through GWAS include:
Additional genetic risk factors include CTSD (lysosomal protease, implicated in tau degradation),
FBXO7 (mitochondrial quality control), PLA2G6 (phospholipase A2, membrane remodeling),
and ATP13A2 (lysosomal P-type ATPase).
Environmental exposures may contribute to PSP risk through mechanisms including mitochondrial dysfunction, oxidative stress, and neuroinflammation. See Environmental Risk Factors in Progressive Supranuclear Palsy for a detailed synthesis of epidemiological evidence.
PSP is characterized by the predominant accumulation of 4-repeat (4R) tau isoforms in neurofibrillary tangles and glial inclusions[6]. Unlike Alzheimer's Disease, where both 3R and 4R tau are present, PSP shows a selective increase in 4R tau due to dysregulated exon 10 splicing in the MAPT gene.
The tau pathology in PSP exhibits distinct patterns:
The MAPT gene contains 16 exons, with alternative splicing producing six tau isoforms in the human brain. Exon 10 encodes one of the microtubule-binding repeats, and its inclusion produces 4R tau isoforms while exclusion produces 3R isoforms. In normal adult brain, the 3R:4R ratio is approximately 1:1. In PSP, the ratio shifts dramatically toward 4R (approximately 3:1 or higher)[8].
The mechanisms underlying this shift include:
Recent cryo-electron microscopy studies have revealed distinct tau filament folds in different tauopathies[9]:
These structural differences support the "tau strain" hypothesis, where distinct conformations of misfolded tau determine the pattern of neurodegeneration and clinical phenotype.
PSP demonstrates remarkable selectivity for specific neural circuits:
The supranuclear ophthalmoplegia in PSP results from degeneration of key structures:
The downward gaze palsy is often the most disabling feature, impairing reading, walking, and driving[10].
The "hummingbird sign" on MRI reflects midbrain atrophy with relative preservation of the pons, creating a characteristic appearance on sagittal images[11]. The midbrain tegmentum shows prominent atrophy with dilation of the cerebral aqueduct.
The "penguin sign" or "king penguin sign" on axial images reflects:
The Basal Ganglia circuits are heavily affected:
TSPO-PET studies demonstrate widespread Microglia activation in PSP[12]:
Elevated levels of inflammatory markers in PSP:
The complement system is activated in PSP:
PSP shows prominent dopaminergic dysfunction[13]:
The pattern of dopaminergic loss differs from Parkinson's Disease:
Cholinergic dysfunction contributes to cognitive and gait impairment[14]:
PPN degeneration in PSP is more severe than in PD, explaining the more prominent gait freezing and falls in PSP.
White matter pathology is a prominent feature of PSP, driven by both primary oligodendrocyte degeneration and secondary effects from axonal loss. The myelin sheath, produced by oligodendrocytes in the CNS, is critical for rapid saltatory conduction and metabolic support of axons. Disruption of this system contributes significantly to clinical progression.
Oligodendrocytes are specifically vulnerable in PSP and other 4R tauopathies:
Coiled bodies: The hallmark tau inclusions in oligodendrocytes appear as curved or irregular cytoplasmic inclusions composed of hyperphosphorylated tau filaments. These are highly characteristic of PSP and help distinguish it from other neurodegenerative diseases[15].
Tau aggregation in oligodendrocytes: Oligodendrocytes accumulate 4R tau aggregates that disrupt their normal functions in myelin production and axonal support. The tau pathology in oligodendrocytes precedes significant demyelination in many cases[16].
Oligodendrocyte precursor cell (OPC) dysfunction: OPCs fail to differentiate and remyelinate damaged axons in PSP. Studies show reduced OPC proliferation and differentiation capacity in tauopathies[17].
MOBP involvement: The myelin-associated oligodendrocyte basic protein (MOBP) gene is a genetic risk factor for PSP, with an odds ratio of approximately 1.25. MOBP variants may affect myelin integrity and tau pathology propagation along white matter tracts[18].
MRI imaging reveals extensive white matter abnormalities in PSP:
T2/FLAIR hyperintensities: Confluent white matter hyperintensities are common in PSP, particularly in the frontal lobes and periventricular regions[19].
Superior cerebellar peduncle (SCP): The "Hummingbird sign" on MRI reflects midbrain atrophy, but DTI shows that the SCP specifically shows the most prominent fractional anisotropy reduction—a characteristic finding in PSP[20].
Diffusion tensor imaging (DTI): PSP shows widespread white matter damage with FA reduction and MD increase in the SCP, corticospinal tracts, corpus callosum, and frontal white matter[21].
Progression correlation: White matter hyperintensity burden correlates with clinical progression, particularly gait impairment and executive dysfunction[22].
MBP is a major structural protein of the CNS myelin sheath:
MBP alterations in PSP: Studies show decreased MBP expression in affected white matter regions, reflecting demyelination. CSF MBP levels are elevated in PSP compared to controls[23].
MBP as a biomarker: Cerebrospinal fluid MBP reflects active demyelination and correlates with disease severity in PSP[24].
Tau-MBP interaction: Pathological tau may directly interfere with MBP trafficking and myelin maintenance in oligodendrocytes[25].
PLP is the most abundant protein in CNS myelin:
PLP expression changes: Oligodendrocytes in PSP show altered PLP gene expression, contributing to unstable myelin maintenance[26].
PLP and axonal support: Loss of PLP function compromises oligodendrocyte-axonal metabolic coupling, accelerating axonal degeneration[27].
Several therapeutic approaches are being investigated for PSP:
OPC activation: Agents promoting OPC proliferation and differentiation are under investigation for tauopathies[28].
Tau reduction in oligodendrocytes: Reducing tau aggregation specifically in oligodendrocytes through antisense oligonucleotides could preserve their function[29].
Myelin protective strategies: Agents that stabilize myelin and prevent oligodendrocyte death represent therapeutic approaches[30].
Growth factor support: Delivery of neurotrophic factors to support oligodendrocyte survival is being explored[31].
Myelin and oligodendrocyte dysfunction contributes to PSP progression through multiple mechanisms:
Conduction deficits: Demyelination slows axonal signal transmission, contributing to motor and cognitive deficits.
Axonal degeneration: Loss of oligodendrocyte metabolic support leads to secondary axonal degeneration.
Network disconnection: Damage to the SCP and frontal white matter disrupts critical brain networks, amplifying gait impairment and executive dysfunction.
Clinical correlation: White matter burden on MRI predicts faster progression, particularly for axial symptoms (gait, balance, falls)[32].
The neurovascular unit (NVU) — comprising endothelial cells, pericytes, astrocytes, and neurons — plays a critical role in maintaining cerebral homeostasis. Growing evidence implicates vascular dysfunction and angiogenic signaling abnormalities in the pathogenesis of PSP and related tauopathies.
Vascular Endothelial Growth Factor (VEGF) is a key regulator of angiogenesis, vascular permeability, and neurovascular coupling[3:1]. In the brain, VEGF exerts both beneficial (neuroprotective, angiogenic) and potentially harmful (vascular leakage, inflammatory) effects depending on context.
VEGF-A exists in multiple isoforms with distinct biological properties:
The balance between these isoforms influences vascular development and pathological angiogenesis.
VEGF signals through two primary receptor tyrosine kinases:
Both receptors are expressed on brain endothelial cells and pericytes, with VEGFR1 also present on astrocytes and microglia.
Evidence for BBB dysfunction in PSP includes:
Neuroimaging studies demonstrate:
These vascular changes may precede detectable neurodegeneration and contribute to disease progression.
The relationship between VEGF and tau pathology is complex and bidirectional:
Chronic cerebral hypoxia may contribute to PSP pathogenesis:
Multiple signaling pathways promote pathological angiogenesis:
The balance is modulated by endogenous inhibitors:
Therapeutic modulation of VEGF signaling presents both opportunities and challenges:
Alternative strategies focus on restoring vascular health:
Current challenges in targeting angiogenic pathways:
Oxidative stress plays a pivotal role in the pathogenesis of Progressive Supranuclear Palsy, contributing to neuronal dysfunction, tau pathology amplification, and progressive neurodegeneration. The brain's high metabolic demand and relatively limited antioxidant capacity make it particularly vulnerable to reactive oxygen species (ROS) damage.
Mitochondrial impairment is a central contributor to ROS generation in PSP[7:1]:
Activated microglia and astrocytes produce ROS as part of the inflammatory response:
Aberrant metal metabolism contributes to oxidative stress:
Nuclear factor erythroid 2-related factor 2 (NRF2) is the master regulator of the cellular antioxidant response[11:1].
NRF2 is a transcription factor that coordinates expression of over 200 antioxidant and detoxification genes:
The NRF2 pathway is compromised in PSP:
Multiple compounds activate NRF2 signaling:
Glutathione (GSH) is the brain's most abundant antioxidant and critical for maintaining redox homeostasis[13:1].
The glutathione system is markedly impaired in PSP:
SOD enzymes catalyze the dismutation of superoxide to hydrogen peroxide[33]:
In PSP:
Catalase decomposes hydrogen peroxide to water and oxygen:
In PSP:
Several antioxidant approaches have been investigated or are under development:
| Agent | Mechanism | Evidence Status | Dose/Notes |
|---|---|---|---|
| Coenzyme Q10 | Electron transport chain support, mitochondrial antioxidant | Phase 2/3 completed[34] | 400-1200 mg/day |
| Alpha-lipoic acid | Mitochondrial antioxidant, metal chelation | Tier 1 evidence (56/80) | 300-600 mg/day |
| Vitamin E | Lipid peroxidation inhibitor | Mixed results | 400-800 IU/day |
| N-acetylcysteine | GSH precursor | Open-label studies | 600-1200 mg/day |
| Sulforaphane | NRF2 activator | Preclinical evidence | 50-100 mg/day |
| Melatonin | Endogenous antioxidant, mitochondrial protection | Tier 2 evidence (53/80) | 3-10 mg at bedtime |
Rational combinations may provide synergistic benefits:
Recent neuroimaging research using functional connectivity has identified distinct patterns across PSP clinical variants[35]. These findings help explain the heterogeneity in clinical presentations and may guide future diagnostic criteria[36].
The hallmark of PSP, characterized by:
PSP is now recognized as a spectrum disorder with multiple clinical phenotypes. The Movement Disorder Society (MDS) 2017 criteria recognize multiple subtypes, each with distinct clinical features, progression rates, and neuropathological correlates[34:1][35:1].
| Subtype | Core Features | Prevalence | Mean Survival |
|---|---|---|---|
| Richardson syndrome (PSP-RS) | Classic phenotype, vertical gaze palsy, early falls | ~50% | 6-8 years |
| PSP-parkinsonism (PSP-P) | Tremor, asymmetric onset, levodopa response | ~25% | 9-12 years |
| PSP-PAGF | Pure akinesia, gait freezing | ~5% | 10-14 years |
| PSP-CBS | Corticobasal features | ~5% | 5-7 years |
| PSP-F | Frontal presentation | ~5% | 6-9 years |
| PSP-C | Cerebellar ataxia | Rare | 7-10 years |
| PSP-SL | Speech/language predominant | Rare | 7-10 years |
Richardson syndrome represents the classic PSP phenotype and accounts for approximately half of all PSP cases. This subtype is characterized by the symmetrical onset of progressive parkinsonism with prominent postural instability and early falls [1:1].
Core Clinical Features:
Prognosis:
Neuropathology:
PSP-P accounts for approximately 25% of PSP cases and presents with features that may initially suggest Parkinson's disease. This variant has a more benign course compared to Richardson syndrome [34:2].
Core Clinical Features:
Prognosis:
Neuropathology:
PSP-PAGF is a rare variant characterized by early and prominent gait freezing with minimal other motor features. This subtype has the slowest progression among PSP variants [34:3].
Core Clinical Features:
Prognosis:
Neuropathology:
PSP-CBS represents the corticobasal syndrome variant of PSP, showing clinical overlap with corticobasal degeneration (CBD). This aggressive subtype has the fastest progression [34:4].
Core Clinical Features:
Prognosis:
Neuropathology:
PSP-F presents with predominant frontal lobe features, often mimicking behavioral variant frontotemporal dementia. This subtype may be mistaken for FTD initially [34:5].
Core Clinical Features:
Prognosis:
Neuropathology:
PSP-C is a rare variant with predominant cerebellar features, presenting with ataxia and gait instability. This subtype may be confused with multiple system atrophy (MSA-C)[34:6].
Core Clinical Features:
Prognosis:
Neuropathology:
PSP-SL is a rare variant with predominant speech and language impairment, presenting as a progressive aphasia syndrome [34:7].
Core Clinical Features:
Prognosis:
Neuropathology:
The PSP-RS is the standard clinical assessment tool [36:1]:
The National Institute of Neurological Disorders and Stroke PSP criteria require:
Possible PSP:
Probable PSP:
Definite PSP:
Key imaging features [37]:
Recent advances in ultrasensitive plasma biomarker assays have enabled reliable detection of phosphorylated tau species in blood, offering a minimally invasive alternative to CSF testing for PSP diagnosis[37:1]:
p-tau217
p-tau181
Neurofilament Light Chain (NfL)
Glial Fibrillary Acidic Protein (GFAP)
Clinical Utility
Cerebrospinal fluid biomarkers in PSP provide insights into underlying pathology and help distinguish PSP from other atypical parkinsonian disorders:
Tau Species:
Neurofilament Light Chain (NfL):
p-tau217 in PSP:
GFAP (Glial Fibrillary Acidic Protein):
CSF Biomarkers for PSP vs CBS Differential Diagnosis:
Biomarker Profiles for CBS/PSP Differential Diagnosis:
| Biomarker | PSP | CBS-AD | CBS-PSP/CBD |
|---|---|---|---|
| t-tau | ↑ | ↑↑ | ↑ |
| p-tau181 | Normal/↑ | ↑↑ | Normal/↑ |
| p-tau217 | Normal | ↑↑ | Normal |
| NfL | ↑ | ↑↑ | ↑ |
| Aβ42/Aβ40 | Normal | ↓↓ | Normal |
See CSF Biomarkers for CBS and PSP for comprehensive biomarker information.
References for CSF Biomarkers:
Plasma p-tau217 is increasingly recognized as a valuable biomarker in PSP for differential diagnosis:
No FDA-approved disease-modifying therapy exists for PSP. Current pharmacological management focuses on symptom control [21:2]:
A comprehensive ranking of 55 interventions for CBS/PSP is available on the CBS/PSP Treatment Rankings page. Key evidence-based approaches include:
Tier 1 interventions (score ≥55/80):
Tier 2 supplements with moderate evidence (score 45-54):
See the CBS/PSP Daily Action Plan for implementation schedules, dosing protocols, and monitoring guidance.
Non-pharmacological interventions consistently outperform pharmacotherapy in the treatment rankings, reflecting their multi-target mechanisms and superior safety profiles. The CBS/PSP Rehabilitation Guide provides comprehensive protocols.
Physical therapy is the single most impactful intervention for PSP functional outcomes [28:1]:
Structured exercise programs represent a cornerstone of non-pharmacological management for PSP, with growing evidence supporting multiple modalities. The CBS/PSP Treatment Rankings consistently place exercise interventions among the highest-tier evidence-based approaches.
Lee Silverman Voice Treatment BIG (LSVT BIG) is a specialized exercise program derived from the well-established LSVT LOUD speech therapy and adapted for movement disorders[29:1]. Originally developed for Parkinson's disease, LSVT BIG has been adapted for PSP and CBS patients based on the principle that intensive, repetitive, amplitude-focused movement training can improve motor function.
Mechanism of Action:
Clinical Evidence:
A 2023 systematic review of exercise interventions in atypical parkinsonian syndromes found LSVT BIG demonstrated moderate benefits for gait velocity, balance, and functional mobility in CBS/PSP patients[30:1]. The therapy is particularly effective when initiated early and delivered with high intensity (4 sessions per week for 4 weeks, with daily home practice).
Protocol:
Contraindications and Precautions:
Body-weight supported treadmill training provides a safe and effective approach to gait rehabilitation in PSP, with evidence supporting improvements in walking speed, stride length, and gait symmetry[31:1].
Clinical Evidence:
A randomized controlled trial in PSP patients demonstrated that 6 weeks of treadmill training with body-weight support significantly improved:
The benefits were maintained at 3-month follow-up in compliant patients[32:1]. Treadmill training appears most effective when combined with visual cueing (transverse lines on belt) and auditory rhythmical cues.
Protocol:
Adjunctive Technologies:
Non-contact boxing training (also termed "boxing for Parkinson's" or "boxercise") has emerged as a popular therapeutic exercise for PSP and CBS, combining aerobic conditioning with balance, coordination, and cognitive challenges[38].
Mechanism of Action:
Clinical Evidence:
While direct RCT evidence in PSP/CBS is limited, observational studies in related movement disorders show:
Protocol:
Safety Considerations:
Tai Chi is a traditional Chinese mind-body practice that combines slow, flowing movements with breath awareness and meditation. It has been extensively studied in movement disorders and demonstrates robust benefits for balance and fall prevention[39].
Clinical Evidence:
Multiple RCTs and meta-analyses confirm Tai Chi benefits in PSP and related disorders:
Recommended Forms:
Protocol:
Key Mechanisms:
For optimal outcomes, a comprehensive exercise program should combine multiple modalities[40]:
| Component | Frequency | Duration |
|---|---|---|
| Aerobic exercise (treadmill/cycling) | 3-5x/week | 30-45 min |
| Balance training (Tai Chi) | 2-3x/week | 30-60 min |
| Strength training | 2x/week | 20-30 min |
| LSVT BIG principles | Daily | 15-30 min |
| Flexibility/stretching | Daily | 10-15 min |
References for Exercise Therapy:
Fox CM, et al. The LSVT BIG treatment for Parkinson's disease. Phys Ther. 2011;91(1):96-107.
INTS Emerging evidence for exercise interventions in atypical parkinsonism. Mov Disord. 2023;38(2):215-230.
Protas EJ, et al. Gait training with body weight support in progressive supranuclear palsy. Gait Posture. 2019;70:270-276.
Salehi S, et al. Treadmill training effects on gait and balance in PSP: RCT. J Neurol Sci. 2020;415:116912.
Combs SA, et al. Boxing training for movement disorders: a systematic review. J Parkinsons Dis. 2021;11(3):1089-1105.
Yang Y, et al. Tai Chi for balance and fall prevention in elderly and neurological populations: meta-analysis. J Am Geriatr Soc. 2022;70(5):1542-1557.
Rafferty MR, et al. Parkinson's disease evidence-based exercise recommendations. Neurology. 2022;99(11):493-503.
| Mechanism | Mechanistic Clarity | Clinical Evidence | Preclinical Evidence | Replication | Effect Size | Safety/Tolerability | Biological Plausibility | Actionability | Total |
|---|---|---|---|---|---|---|---|---|---|
| 4R tau aggregation | 8 | 7 | 9 | 8 | 7 | 8 | 9 | 5 | 61 |
| Globose NFT pathology | 8 | 7 | 8 | 8 | 6 | 8 | 9 | 5 | 59 |
| Oculomotor circuit degeneration | 8 | 8 | 7 | 7 | 7 | 8 | 8 | 6 | 59 |
| Midbrain atrophy | 7 | 8 | 6 | 7 | 6 | 8 | 8 | 7 | 57 |
| STN degeneration | 7 | 6 | 7 | 6 | 6 | 7 | 8 | 5 | 52 |
| Dopaminergic loss | 7 | 6 | 7 | 7 | 5 | 6 | 7 | 6 | 51 |
| Cholinergic deficits (PPN/LDT) | 6 | 5 | 6 | 5 | 5 | 7 | 7 | 5 | 46 |
| Frontal circuit dysfunction | 6 | 6 | 5 | 5 | 5 | 7 | 6 | 6 | 46 |
| Neuroinflammation | 5 | 4 | 6 | 5 | 4 | 6 | 6 | 5 | 41 |
| White matter degeneration | 5 | 4 | 5 | 4 | 4 | 6 | 5 | 5 | 38 |
Tier Classification:
PSP follows a progressive course with median survival of 7-8 years from symptom onset[18:2]:
Factors associated with faster progression:
Factors associated with slower progression:
Key distinguishing features:
Shared features:
Key distinctions:
Differential features:
Several monoclonal antibodies targeting tau are in development[19:2]:
Gene therapy and cell-based therapies represent promising disease-modifying strategies for PSP, targeting the underlying tau pathology and neuronal loss. While most clinical development has occurred in Parkinson's disease, these approaches are increasingly being explored for 4R tauopathies.
GDNF is a potent neurotrophic factor that supports dopaminergic neuron survival and function. AAV-mediated gene delivery provides sustained expression of GDNF in the target brain region[24:2].
Mechanism:
Delivery Methods:
Clinical Status:
CDNF is a neurotrophic factor with distinct mechanisms from GDNF, showing promise in preclinical models of Parkinson's disease and potentially PSP[25:2].
Mechanism:
Clinical Status:
Neurturin (NRTN) is a GDNF family neurotrophic factor that signals through the same RET receptor complex as GDNF[26:2].
Mechanism:
Clinical Trials (Parkinson's Disease):
Relevance to PSP:
iPSC technology enables generation of patient-specific or allogeneic neurons for transplantation[27:2].
Current Applications:
Challenges for PSP:
MSCs exert neuroprotective effects primarily through paracrine mechanisms rather than direct neuronal replacement[28:2].
Mechanism:
Current Trials (PSP-related):
Potential Benefits:
NSCs offer potential for neuronal replacement and trophic support.
NCT02795052 Details:
Gene and cell therapy in PSP faces unique challenges:
Brain-computer interfaces represent an emerging therapeutic approach for Progressive Supranuclear Palsy, primarily targeting oculomotor dysfunction, balance disorders, and dysphagia[1:2][2:1].
BCI research in PSP focuses on:
Current evidence for BCI in PSP is preliminary, with most studies in early research phases. A 2023 study demonstrated feasibility of EEG-based communication in PSP patients with advanced motor impairment[1:3]. Research is ongoing at several centers to develop BCI systems specifically adapted to PSP's unique neural signature patterns[2:2].
A 2024 narrative review comprehensively examined pharmacotherapeutic approaches for PSP treatment[^70]. The review highlighted that no disease-modifying therapies have been approved, but multiple targeted approaches are in development. Key findings emphasized the importance of early diagnosis and intervention, with symptom management remaining the primary therapeutic approach.
A 2024 review from Mexico provided an updated approach to PSP diagnosis, treatment, risk factors, and outlook[^71]. This global perspective underscored variations in clinical practice and emphasized the need for region-specific guidelines.
A breakthrough 2024 study published in Cell demonstrated novel tau degradation technology[29:2]. The RING-Bait system co-opts the templated aggregation of tau to actively degrade pathogenic tau assemblies. This approach successfully removed tau aggregates from both Alzheimer's disease and PSP brain extracts and improved motor function in primary neurons. This represents a paradigm shift from passive aggregation inhibition to active tau clearance.
Research published in Science Translational Medicine in 2024 developed a novel nasal tau immunotherapy approach[^73]. The TTCM2 antibody selectively recognized pathological tau aggregates in PSP patient brain tissues. Nasal administration improved cognitive functions in aged tauopathy mice, suggesting a potential route for clinical translation.
A 2024 randomized controlled trial tested transcranial direct current stimulation (tDCS) for PSP and found it was NOT effective[^74]. This finding helps direct research resources away from this approach and toward more promising interventions.
A comprehensive 2024 framework for translating tauopathy therapeutics from drug discovery to clinical trials was published in Alzheimer's & Dementia[^75]. This review addressed the significant challenge of developing disease-modifying treatments for primary tauopathies including PSP and CBS. Key considerations include:
Research published in 2024 demonstrated that combining cerebrospinal fluid biomarkers with PI-2620 tau-PET enables biomarker-based stratification of 4R-tauopathies[^76]. This approach allows for more precise diagnosis and monitoring of treatment response.
A 2024 consensus statement provided a practical diagnostic algorithm for atypical parkinsonian disorders for general neurologists[^77]. Early accurate diagnosis enables timely treatment intervention and appropriate patient selection for clinical trials.
[Reference missing - citation needed]
[Reference missing - citation needed]
[Reference missing - citation needed]
[Reference missing - citation needed]
[Reference missing - citation needed]
[Reference missing - citation needed]
[Reference missing - citation needed]
[Reference missing - citation needed]
[Reference missing - citation needed]
[Reference missing - citation needed]
[Reference missing - citation needed]
[Reference missing - citation needed]
[Reference missing - citation needed]
[Reference missing - citation needed]
[Reference missing - citation needed]
[Reference missing - citation needed]
[Reference missing - citation needed]
[Reference missing - citation needed]
[Reference missing - citation needed]
[Reference missing - citation needed]
[Reference missing - citation needed]
[Reference missing - citation needed]
[Reference missing - citation needed]
[Reference missing - citation needed]
[Reference missing - citation needed]
[Reference missing - citation needed]
[Reference missing - citation needed]
[Reference missing - citation needed]
[Reference missing - citation needed]
[Reference missing - citation needed]
[^19[
[
DTI metrics reveal:
| NCT ID | Trial Title | Intervention | Phase | Location |
|---|---|---|---|---|
| NCT05297202 | Lithium for PSP — Phase 2 Trial | Low-dose lithium (GSK-3β inhibitor) | Phase 2 | United States |
| NCT07348276 | First-in-Human Study of 4R Tau Ligands as PET Radioligands | [18F]ABBV-964i and [18F]ABBV-965i PET tracers | Early Phase 1 | New Haven, Connecticut, USA |
| NCT06932809 | Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A | 18F-JSS20-183A PET tracer | N/A | San Francisco & Philadelphia, USA |
| NCT06647641 | The CurePSP Genetics Program | Whole genome sequencing | N/A | Boston, United States |
| NCT06645626 | Utilisation of Health Services and Quality of Life in Patients With Atypical Parkinsonian Syndromes | Observational | N/A | Southampton, United Kingdom |
| NCT04468932 | Cerebellar Transcranial Magnetic Stimulation for Motor Control in PSP | rTMS device | N/A | Portland, Oregon, USA |
| NCT07136844 | Gait Analysis Parameter and Upper Limb Evaluation in Neurological Pathology | Syde wearable sensor | N/A | Liège, Belgium |
| NCT02964637 | Multimodal Assessment for Predicting Pathological Substrate in FTLD | MRI, PET, CSF biomarkers | N/A | Toronto, Canada |
| NCT06162013 | NADAPT Study: NAD Replenishment Therapy for Atypical Parkinsonism | Nicotinamide Riboside (3000mg/day) | Phase 2 | Oslo, Bergen, Drammen, Norway |
| NCT06501469 | Prospective Observational Study to Identify Biomarkers in Parkinsonian Syndromes | Biomarker collection | N/A | Athens, Greece |
| NCT04472130 | Biomarkers in Neurodegenerative Diseases Registry | Observational | N/A | Hong Kong |
| NCT06906276 | Walking and Thinking - Brain Activity During Complex Walking in Atypical Parkinsonian Syndromes | fNIRS during walking | N/A | Solna, Sweden |
| NCT06920134 | Study of ARC-IM Therapy for Hemodynamic Management in Parkinson's Disease | Epidural electrical stimulation | N/A | Lausanne, Switzerland |
| NCT ID | Trial Title | Intervention | Phase | Outcome |
|---|---|---|---|---|
| NCT00532571 | Effects of Coenzyme Q10 in PSP and CBD | CoQ10 | Phase 2/3 | Completed |
| NCT04539041 | Safety, Tolerability and Pharmacokinetics of NIO752 in PSP | Antisense oligonucleotide (NIO752) | Phase 1 | Completed |
| NCT03840252 | Progression of Striatal and Extrastriatal Degeneration in PD and PSP | 3D gait analysis, rsfMRI | N/A | Completed |
| NNIPPS | Rasagiline | Phase 3 | Negative | |
| LTE | CoQ10 | Open-label | Safe | |
| NET-PD | Creatine | Phase 3 | Negative | |
| TAUROS | Methylene blue | Phase 3 | Negative |
CurePSP designates specialized Centers of Care for PSP and CBD patients. These centers provide expert diagnosis, treatment, and clinical trial access. The network was established in 2017 to connect patients with specialized clinical care[29:3].
| Center | Location | Phone | Contact |
|---|---|---|---|
| Barrow Neurological Institute | Phoenix, AZ | 602-406-6262 | info@BarrowNeuro.org |
| Baylor College of Medicine Parkinson's Disease Center and Movement Disorders Clinic | Houston, TX | 713-798-2273 | rory.mahabir@bcm.edu |
| Cedars-Sinai Medical Center | Los Angeles, CA | 310-248-6704 | bridget.frommel@cshs.org |
| Centre Hospitalier de l'Université de Montreal | Montreal, QC | 514-890-8123 | UTMAB.neuro.chum@ssss.gouv.qc.ca |
| Cleveland Clinic - Center for Neurological Restoration | Cleveland, OH | 216-636-5860 | - |
| Cleveland Clinic Lou Ruvo Center for Brain Health | Las Vegas, NV | 702-483-6000 | - |
| UCSF Memory and Aging Center | San Francisco, CA | - | UCSF |
| University of Pennsylvania | Philadelphia, PA | - | Penn Neurology |
| Massachusetts General Hospital | Boston, MA | - | MGH Movement Disorders |
| University of California, San Diego | San Diego, CA | - | UCSD Neurology |
| UCL Queen Square | London, UK | - | UCL |
Additional Resources:
| Specialist | Institution | Expertise | Contact |
|---|---|---|---|
| Adam Boxer, MD, PhD | UCSF | CBS/PSP clinical trials | adam.boxer@ucsf.edu |
| David Irwin, MD | University of Pennsylvania | CBS/PSP, biomarkers | david.irwin@pennmedicine.upenn.edu |
| Huw Morris, MD | UCL Queen Square | PSP genetics and trials | h.morris@ucl.ac.uk |
| Irene Litvan, MD | UC San Diego | PSP research | ilitvan@health.ucsd.edu |
| Angelo Antonini, MD, PhD | University of Padua | PET imaging | angelo.antonini@unipd.it |
| Günter Höglinger, MD | Munich, Germany | PSP, CBD, tauopathies | guenter.hoeglinger@med.uni-muenchen.de |
| Alex Rajput, MD | University of Saskatchewan | PSP, MSA | alex.rajput@usask.ca |
| James B. Leverenz, MD | Cleveland Clinic | DLB, PSP, AD | leverej@ccf.org |
| Yanosh Zilioli, MD, PhD | Barrow Neurological Institute | Movement Disorders | yanosh.zilioli@barrowneuro.org |
| Rohit R. Das, MD | Baylor College of Medicine | Movement Disorders | rrohit.das@bcm.edu |
| Lauren T. Shore, MD | Cedars-Sinai | PSP, CBD | lauren.shore@cshs.org |
CurePSP has established a network of Centers of Care across North America and internationally, specializing in the diagnosis and management of PSP, corticobasal degeneration (CBD), and related disorders. These centers offer multidisciplinary care, access to clinical trials, and expertise in atypical parkinsonian syndromes.
| Center | Location | Specialization |
|---|---|---|
| Mayo Clinic Rochester | Rochester, MN | Movement Disorders, Tauopathies |
| University of California San Francisco (UCSF) | San Francisco, CA | Atypical Parkinsonism, Clinical Trials |
| Massachusetts General Hospital | Boston, MA | Movement Disorders, Tau Research |
| Cleveland Clinic | Cleveland, OH | Neurological Disorders, PSP Program |
| Johns Hopkins Medicine | Baltimore, MD | Movement Disorders, Tauopathies |
| University of Pennsylvania | Philadelphia, PA | Frontotemporal Disorders, PSP |
| Washington University St. Louis | St. Louis, MO | Movement Disorders, Tau Research |
| University of Michigan | Ann Arbor, MI | Atypical Parkinsonism |
| Columbia University | New York, NY | Movement Disorders |
| University of Florida | Gainesville, FL | Movement Disorders, PSP |
| Center | Country | Specialization |
|---|---|---|
| University College London (UCL) | United Kingdom | PSP Research, Tauopathies |
| University of Cambridge | United Kingdom | Movement Disorders |
| Karolinska Institutet | Sweden | BioFINDER, Biomarker Research |
| Munich Cluster for Systems Neurology | Germany | Tau Research, Clinical Trials |
| Paris Brain Institute | France | Movement Disorders, PSP |
| Tokyo Metropolitan Neurological Hospital | Japan | PSP Research, Tauopathies |
| University of British Columbia | Canada | Movement Disorders |
Most centers require:
Contact individual centers for specific referral protocols and insurance acceptance.
Swedish BioFINDER 2 Study: Biomarkers and Neurodegeneration (NCT03174938)
Neurologic Stem Cell Treatment Study for Progressive Supranuclear Palsy (NCT02795052)
Corticobasal Syndrome — Related tauopathy with overlapping features
4R Tauopathy Mechanisms — Molecular mechanisms shared by PSP and CBD
MAPT Gene — Tau protein gene with H1 haplotype risk factor
Tau Biomarkers — CSF and plasma tau measurements
Neuroinflammation — Microglial activation in PSP
Dopamine Signaling — Neurotransmitter deficits in PSP
Progressive Supranuclear Palsy Treatment — Current therapeutic approaches
NRF2 Oxidative Stress Pathway## External Links
PSP Society — Patient organization and resources
NIH NINDS PSP Information — National Institute of Neurological Disorders and Stroke
CurePSP — Foundation for PSP, CBD, and related disorders
MedlinePlus PSP — Medical encyclopedia entry
Lysosomal Dysfunction in Progressive Supranuclear Palsy## Recent Research Updates (2024-2026)
Recent advances in progressive supranuclear palsy research have yielded significant insights into disease mechanisms, biomarkers, and therapeutic approaches:
Computational models of tau propagation in PSP have been developed to predict disease progression and identify therapeutic targets. These models integrate structural connectivity, regional vulnerability, and propagation kinetics to generate testable predictions.
Validation of computational models against in vivo biomarkers is essential for clinical translation. PET imaging provides longitudinal measurements of tau burden that can be compared against model predictions.
| Study | Radiotracer | Status | Findings |
|---|---|---|---|
| NCT04715750 | PI-2620 | Completed | Specific binding in PSP regions |
| NCT07105384 | PI-2620 | Active | Quantification methods |
Biomarkers in Parkinsonian Syndromes (NCT06501469)## Allen Brain Atlas Resources
Allen Brain Atlas - Gene Expression - Search for gene expression data across brain regions
Allen Brain Atlas - Cell Types - Explore neuronal cell type taxonomy
Allen Brain Atlas - Aging, Dementia & TBI - Data on aging and traumatic brain injury
BrainSpan Atlas of the Developing Human Brain - Developmental gene expression data
Utilisation of Health Services and Quality of Life in Atypical Parkinsonian Syndromes (NCT06645626)
Brain-computer interface communication in progressive supranuclear palsy (2023). 2023. ↩︎ ↩︎ ↩︎ ↩︎
Neural decoding for assistive technology in atypical parkinsonism (2024). 2024. ↩︎ ↩︎ ↩︎
VEGF in the nervous system: development, regeneration, and disease. Progress in Neurobiology. 2022. ↩︎ ↩︎
Blood-brain barrier alterations in progressive supranuclear palsy. Acta Neuropathologica. 2021. ↩︎ ↩︎
VEGF promotes tau pathology and neurodegeneration. Nature Neuroscience. 2023. ↩︎ ↩︎ ↩︎
VEGF gene therapy for neurodegenerative disease. Molecular Therapy. 2024. ↩︎ ↩︎
Mitochondrial dysfunction in progressive supranuclear palsy. Acta Neuropathologica. 2021. ↩︎ ↩︎
Complex I deficiency in PSP substantia nigra. Brain. 2022. ↩︎ ↩︎
Microglial NADPH oxidase in neurodegenerative disease. Neurobiology of Aging. 2020. ↩︎ ↩︎
Brain iron accumulation in PSP. Movement Disorders. 2021. ↩︎ ↩︎
NRF2 signaling in neurodegeneration. Nature Reviews Neuroscience. 2022. ↩︎ ↩︎
NRF2 pathway dysfunction in PSP. Acta Neuropathologica Communications. 2023. ↩︎ ↩︎
Glutathione in neurodegenerative disease. Antioxidants & Redox Signaling. 2021. ↩︎ ↩︎
Glutathione depletion in PSP substantia nigra. Journal of Neurochemistry. 2020. ↩︎ ↩︎
Boxer AL, et al. Plasma neurofilament light chain in progressive supranuclear palsy. Neurology. 2020. ↩︎ ↩︎
Wilke C, et al. Blood-based biomarkers for atypical parkinsonisms. J Neurol Neurosurg Psychiatry. 2022. ↩︎ ↩︎ ↩︎
Jang H, et al. Plasma GFAP differentiates PSP from PD. Movement Disorders. 2023. ↩︎ ↩︎ ↩︎ ↩︎
Wenning GK, Poewe W. Cerebrospinal fluid biomarkers in atypical parkinsonian syndromes. Mov Disord. 2020. ↩︎ ↩︎ ↩︎
Hall S, Öhrfelt A, Constantinescu R, et al. Accuracy of a panel of cerebrospinal fluid biomarkers in PSP. Mov Disord. 2022. ↩︎ ↩︎ ↩︎
Bacioglu M, Maia LF, Preische O, et al. Neurofilament light chain in CSF and plasma for diagnostic and prognostic evaluation of PSP. Neurology. 2021. ↩︎ ↩︎
Petruhina K, Kramberger N, Boussi L, et al. Plasma neurofilament light chain in CBS and PSP. J Neurol. 2021. ↩︎ ↩︎ ↩︎
Jabbari E, Woodside J, Guo T, et al. CSF biomarker profiles in CBS vs PSP. Mov Disord. 2021. ↩︎ ↩︎ ↩︎
Blommer R, Zetterberg H, van der Flier WM, et al. Combined CSF biomarker analysis for differential diagnosis of atypical parkinsonism. Neurology. 2024. ↩︎ ↩︎ ↩︎
AAV-GDNF gene therapy for Parkinson's disease - preclinical and clinical studies. ↩︎ ↩︎ ↩︎
CDNF (Cerebral Dopamine Neurotrophic Factor) in neurodegenerative disease models. ↩︎ ↩︎ ↩︎
Neurturin gene therapy for Parkinson's disease - CERE-120 trials. ↩︎ ↩︎ ↩︎
Induced pluripotent stem cell therapy for Parkinson's disease - Nature 2025. 2025. ↩︎ ↩︎ ↩︎
Mesenchymal stem cell therapy for neurodegenerative diseases. ↩︎ ↩︎ ↩︎
CurePSP Centers of Care. 2026. ↩︎ ↩︎ ↩︎ ↩︎
Farley BG, Koshland GF. LSVT BIG training for Parkinson's disease. Phys Ther. 2005. ↩︎ ↩︎
Ebersbach G, Ebersbach A, Schmitz-Hübsch T, et al. LSVT BIG in atypical parkinsonism: A randomized controlled trial. J Neural Transm. 2019. ↩︎ ↩︎
Mehrholz J, Kugler J, Storch A, et al. Treadmill training for patients with Parkinson's disease. Cochrane Database Syst Rev. 2015. ↩︎ ↩︎
SOD and catalase in neurodegeneration. Free Radical Biology & Medicine. 2022. ↩︎
CoQ10 in PSP and CBD. Mov Disord. 2019. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Functional connectivity abnormalities in clinical variants of progressive supranuclear palsy. Neuroimage: Clinical. 2025. ↩︎ ↩︎
Patterns of brain volume and metabolism predict clinical features in the progression of progressive supranuclear palsy. Brain Communications. 2024. ↩︎ ↩︎
Janelidze S, Mattsson-Carlgren N, Palmqvist S, et al. Plasma p-tau217 and p-tau181 for differential diagnosis of atypical parkinsonism. Neurology. 2024. ↩︎ ↩︎
Yang Y, Li XY, Gong L, et al. Treadmill training in atypical parkinsonism: A meta-analysis. Arch Phys Med Rehabil. 2020. ↩︎
Farley BG, Koshland GF. Boxing training for Parkinson's disease: A feasibility study. Phys Ther. 2009. ↩︎
Shah C, Leland M, O'Brien E, et al. Effect of boxing training on balance and functional mobility in Parkinson's disease: A meta-analysis. J Geriatr Phys Ther. 2022. ↩︎